Spyre Therapeutics raised $350 million, taking total capital raised since inception to more than $2 billion. The funding will support late-stage development of SPY072 for hidradenitis suppurativa, with pro forma cash of about $1.5 billion.
published
Spyre Therapeutics raised $350 million, taking total capital raised since inception to more than $2 billion. The funding will support late-stage development of SPY072 for hidradenitis suppurativa, with pro forma cash of about $1.5 billion.
Latest documented BWB result
$SECZ market result
Exit $SECZ with .95 profit per share - thanks to a nice after hours pop. Will re-enter tomorrow most likely
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.